New combo before surgery for low rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your rectal cancer must be locally advanced and low (within 4 inches of the anus) and have a specific protein pattern called pMMR.
- You must have good organ function (like bone marrow, liver, and kidneys) as shown by blood tests.
- You must not have had another cancer in the last 5 years (except for some very early or cured cancers).
- You must not have serious, uncontrolled health problems like heart disease, high blood pressure, or diabetes.
- You must agree to use effective birth control during and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining radiation and chemotherapy with two immunotherapy drugs can better treat locally advanced rectal cancer (no spread to distant organs). It may shrink the tumor before surgery, and if you are enrolled, you will receive this combination as part of the study.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial tests giving radiation and chemotherapy plus an immunotherapy medicine called tislelizumab before surgery for locally advanced rectal cancer. It aims to shrink the tumor and increase the chance of fully removing it safely (R0 resection).
This trial tests a combination of brief radiation therapy, two chemotherapy drugs (nal-IRI and capecitabine), and an immunotherapy drug (camrelizumab) for locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes before surgery.
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.